Garrett Frampton, associate director of Cancer Genomics at Foundation Medicine, discusses recent research about genetic mutations that are more common in certain age groups.
Garrett Frampton, associate director of Cancer Genomics at Foundation Medicine, discusses recent research about genetic mutations that are more common in certain age groups.
In a study of more than 100,000 people, Frampton and his team found that younger patients (typically those in their 30s and 40s) tended to have germline alterations, while people who were in their 50s and 60s were more likely to have a much different genetic makeup.
Establishing the methodology for this kind of research is particularly important, Frampton says, as Foundation Medicine will continue to grow its database and take their research to the next steps, which may ultimately play a huge role in treatment decision-making for patients with cancer.
Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited
December 7th 2020In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
Read More
To gain a better understanding of the issues faced by geriatric patients with cancer, and to determine how much of a role nutrition plays in outcomes, Dr. Grant Williams, a geriatrician oncologist and assistant professor at the University of Alabama, Birmingham, worked with colleagues to create a patient-reported assessment tool that bridges the knowledge gap in this patient population.
Read More